IntrinsicIntrinsic
← All summaries

UFP TECHNOLOGIES INC

UFPT
Financials & Chart →

Business Summary

UFP Technologies, Inc. is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. The Company is a vital link in the medical device supply chain and a valued outsourcing partner to many of the world's top medical device manufacturers. The Company's single-use and single-patient devices and components are used in a wide range of medical devices and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants. The global medical market is large and growing but the Company targets specific segments where its development and manufacturing expertise and access to highly specialized materials helps customers differentiate products, improve patient outcomes, and increase their client's speed to market. The product segments the Company targets include minimally invasive surgery, infection control, orthopedics, interventional & surgical, surfaces & support, therapeutics, diagnostics, wound care, and biopharma.

The medical design and contract manufacturing industry is highly competitive as is the foam and plastics converting industry as a whole. The Company's primary competition is from smaller independent regional manufacturing companies. The Company expects to compete effectively due to its ability to address customers' primary vendor selection criteria, including inclusion on their preferred supplier lists, price, product performance, product reliability, manufacturing locations, and customer service, as well as its access to a wide variety of materials, its engineering expertise, its ability to combine foams with other materials such as plastics and laminates, and its ability to manufacture products in a clean room environment. The Company's top ten customers represented approximately 68.8% of total net sales in 2025, 68.1% in 2024, and 59.3% in 2023. Two customers, Intuitive Surgical SARL and Stryker, comprised approximately 24.3% and 21.5% of net sales for the year ended December 31, 2025, respectively.

The Company generates revenue primarily through the sale of custom-engineered products, tooling and machinery, and engineering services. Revenue is recognized when a customer obtains control of a promised good or service. The Company recognizes a significant portion of its product sales upon shipment. Revenue from the sale of tooling and machinery is recognized primarily when the product is effectively manufactured using tooling and machinery, or when customer acceptance is received if stipulated. Revenue from engineering services, primarily product development services, is recognized as the services are performed. Standard payment terms are net 30 days unless contract terms state otherwise. The Company markets and sells its products principally through a direct sales force.

The Company's products, which often are custom-made to its customers' specifications, include protective drapes for robotic surgery, patient handling and comfort, advanced wound care, infection prevention, disposables for surgical and endoscopic procedures, packaging for medical devices and orthopedic implants, components for cardiac implants, dispenser coils for catheters, and biopharma drug manufacturing. For the year ended December 31, 2025, net sales to the medical market were $555.323 million , representing 92.1% of total net sales, while non-medical market net sales were $47.474 million , representing 7.9% of total net sales. Net sales of products were $591.355 million , tooling and machinery were $4.501 million , and engineering services were $6.941 million for the year ended December 31, 2025.

The Company's manufacturing operations consist primarily of cutting, routing, compression and injection molding, vacuum-forming, micro-molding, thermoforming, laminating, radio frequency and impulse welding, and assembling. The Company has nineteen manufacturing locations that are ISO 13485 certified and thirteen that are FDA registered. The Company has a total of 21 active patents relating to technologies primarily in the medical device, foam, and packaging fields, with expiration dates ranging from 2026 through 2044 . The Company's U.S. registered trademarks include UFP TECHNOLOGIES®, UFP MEDTECH®, SHAPING INNOVATION®, FLEXSHIELD®, FIRMALITE®, BIOSHELL®, T-TUBES®, T-TUBE®, TRI-COVERS®, DESIGN NAIL®, PRO-STICKS®, CRYOSHELL®, CASE FIT®, ALLOSHELL®, FLASH SHINER®, MAMBO®, WINEPACKS®, UNITED FOAM®, and the Company's STACKED U LOGO.

During fiscal 2025, the Company completed three acquisitions: AJR Specialty Products and AJR Custom Foam Products on April 25, 2025 for an aggregate purchase price of $2.8 million in cash; Universal Plastics & Engineering Company, Inc. (UNIPEC) on July 2, 2025 for an aggregate purchase price of $7.5 million in cash; and Techno Plastics Industries, Inc. (TPI) on July 7, 2025 for an aggregate purchase price of $4.5 million in cash. The Company also executed a post-acquisition review of its AJR labor force's United States employment eligibility through E-Verify protocols, which resulted in significant workforce turnover and an estimated $6.3 million in incremental labor cost added to cost-of-sales for the year ended December 31, 2025. On or about February 14, 2026, the Company detected a material information technology systems incident (the Cyber Incident) that impacted many but not all of the Company's IT systems and affected functions such as billing and label making for customer deliveries. As of the date of the filing, the Cyber Incident has not had a material impact on the Company's financial systems, operations or financial condition.

Net sales for the year ended December 31, 2025 increased 19.5% to $602.8 million from $504.4 million in the same period last year. The increase was primarily attributable to 23.2% growth in sales to customers in the medical market, largely due to sales from companies acquired in 2024 and 2025, which collectively contributed approximately $168.3 million in sales for the year ended December 31, 2025 compared to $73.1 million in the same period last year. Organic sales growth was 1.5% for the year ended December 31, 2025 as compared to the year ended December 31, 2024. Gross profit as a percentage of net sales decreased to 28.3% for the year ended December 31, 2025, from 29.1% in 2024. Net income was $68.313 million for the year ended December 31, 2025, compared to $58.981 million for the year ended December 31, 2024. Diluted EPS was $8.75 for 2025 versus $7.58 for 2024.

Business Outlook

The Company's current strategy includes further organic growth and growth through strategic acquisitions. The Company plans to continue to add capacity to enhance operating efficiencies in its manufacturing plants and accommodate anticipated growth in demand. The Company may consider additional acquisitions of companies, technologies, or products that are complementary to its business. The Company's Newburyport MA facility utilizes solar power to provide approximately 6% of its electricity, with plans to increase capacity in the future.

The Company's growth strategy also includes expansion of its operations into markets outside of the U.S. The Company has recently added and expanded manufacturing facilities in Puerto Rico, the Dominican Republic, Ireland, Costa Rica, and Mexico. The Company may continue to expand its operations by offering its services and entering new lines of business in other markets outside of the U.S. The Company's international sales to customers outside the U.S. accounted for approximately 16.0% of net sales for 2025.The Company noted that absent the impact on Gross Margins from the AJR Labor Issue, gross margins for the year ended December 31, 2025 would have been 29.3% .

The Company's manufacturing operations consist primarily of cutting, routing, compression and injection molding, vacuum-forming, micro-molding, thermoforming, laminating, radio frequency and impulse welding, and assembling. The Company does not manufacture any of the raw materials used in its products. With the exception of certain grades of cross-linked foam, thermoplastic urethane (TPU) and technical polyurethane foams, these raw materials are available from multiple supply sources. The Company relies upon a limited number of suppliers for cross-linked and technical polyurethane foams, and TPU. As of January 24, 2026, the Company had a total of 4,846 full-time employees (compared to 4,146 full-time employees as of January 25, 2025) and 503 temporary workers (compared to 189 temporary workers at January 25, 2025).The Company did not pay any dividends in 2025 or 2024. The Company presently intends to retain all its earnings to provide funds for the operation of its business and strategic acquisitions, although it would consider paying cash dividends in the future. The Company did not repurchase any shares of common stock during the years ended December 31, 2025, 2024, and 2023.

The Company faces headwinds from inflation, which could affect manufacturing costs, operating expenses (including wages) and other expenses. The Company may not be able to pass these cost increases on to its customers in a timely manner, which could have an impact on gross margins and profitability. The ongoing conflict between Russia and Ukraine, civil unrest in Haiti, and similar conflicts could have a material adverse effect on the Company's business and results of operations. The Company's manufacturing facilities and warehouses in the Dominican Republic play a crucial role in the production of certain of its medical products and may be damaged or disrupted as a result of civil unrest or other occurrences in Haiti.

The Company is subject to risks related to tariffs and trade policy. In 2025, the United States imposed increased tariffs on foreign imports into the United States, including all the countries in which the Company manufactures goods outside the United States and also the countries in which its customers operate. The Company estimates that tariffs not reimbursed by customers were immaterial to its 2025 results. The tariff policy environment remains dynamic and the Company cannot predict what additional actions may ultimately be taken by the United States or other governments with respect to tariffs or trade relations.

Risk Factors

The Company depends on a small number of customers for a large percentage of its net sales. The top ten customers represented approximately 68.8% of total net sales in 2025, and two customers, Intuitive Surgical SARL and Stryker, comprised approximately 24.3% and 21.5% of net sales, respectively, for the year ended December 31, 2025. One customer represented approximately 32.1% of gross accounts receivable at December 31, 2025. The loss of any such customer or a reduction in net sales could have a material adverse effect. The Company experienced a material information technology systems incident in February 2026 (the Cyber Incident) that impacted many IT systems and affected functions such as billing and label making. Certain Company or Company-related data appear to have been stolen or destroyed. While the Company does not currently believe the incident is reasonably likely to materially impact financial condition or results of operations, there can be no assurance that the Cyber Incident or future incidents will not have a material impact. The Company has significant indebtedness, with approximately $135.5 million in outstanding borrowings under the Third Amended and Restated Credit Agreement at December 31, 2025, and is subject to financial covenants including a minimum fixed-charge coverage ratio and a maximum total funded debt to EBITDA ratio. At December 31, 2025, the Company had $338.3 million of goodwill and other intangible assets, representing approximately 51.6% of total assets, and may never realize the full value of these assets.

Management Priorities

Management's message emphasizes the Company's position as a contract development and manufacturing organization specializing in single-use and single-patient medical devices, and a vital link in the medical device supply chain. The current strategy includes further organic growth and growth through strategic acquisitions. Management highlighted that net sales for the year ended December 31, 2025 increased 19.5% to $602.8 million from $504.4 million in the same period last year, with organic sales growth of 1.5% . Management also noted the impact of the AJR Labor Issue, which added over $6.3 million in incremental labor cost to cost-of-sales for the year ended December 31, 2025. Regarding the Cyber Incident detected on or about February 14, 2026, management stated that as of the date of the filing, the incident has not had a material impact on the Company's financial systems, operations or financial condition, and the Company does not believe the incident is reasonably likely to materially impact the Company's financial condition or results of operations. Key strategic priorities emphasized include further organic growth, growth through strategic acquisitions, and adding capacity to enhance operating efficiencies in manufacturing plants to accommodate anticipated growth in demand.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1A, Risk Factors
  2. [2] Item 1A, Risk Factors
  3. [3] Item 1A, Risk Factors
  4. [4] Item 1, Business — Marketing and Net Sales
  5. [5] Item 1, Business — Marketing and Net Sales
  6. [6] Item 8, Note 20 — Segment Data
  7. [7] Item 8, Note 20 — Segment Data
  8. [8] Item 8, Note 20 — Segment Data
  9. [9] Item 8, Note 20 — Segment Data
  10. [10] Item 8, Note 4 — Revenue Recognition
  11. [11] Item 8, Note 4 — Revenue Recognition
  12. [12] Item 8, Note 4 — Revenue Recognition
  13. [13] Item 1, Business — Patents and Other Proprietary Rights
  14. [14] Item 1, Business — Patents and Other Proprietary Rights
  15. [15] Item 8, Note 2 — Acquisitions
  16. [16] Item 8, Note 2 — Acquisitions
  17. [17] Item 8, Note 2 — Acquisitions
  18. [18] Item 7, MD&A — Overview
  19. [19] Item 7, MD&A — Overview
  20. [20] Item 7, MD&A — Overview
  21. [21] Item 7, MD&A — Overview
  22. [22] Item 7, MD&A — Results of Operations
  23. [23] Item 7, MD&A — Overview
  24. [24] Item 7, MD&A — Overview
  25. [25] Item 7, MD&A — Overview
  26. [26] Item 7, MD&A — Results of Operations
  27. [27] Item 7, MD&A — Results of Operations
  28. [28] Item 8, Consolidated Statements of Comprehensive Income
  29. [29] Item 8, Consolidated Statements of Comprehensive Income
  30. [30] Item 8, Consolidated Statements of Comprehensive Income
  31. [31] Item 8, Consolidated Statements of Comprehensive Income
  32. [32] Item 1, Business — Regulatory Climate and Environmental Considerations
  33. [33] Item 8, Note 20 — Segment Data
  34. [34] Item 7, MD&A — Results of Operations
  35. [35] Item 1, Business — Human Capital Management
  36. [36] Item 1, Business — Human Capital Management
  37. [37] Item 1, Business — Human Capital Management
  38. [38] Item 1, Business — Human Capital Management
  39. [39] Item 1A, Risk Factors
  40. [40] Item 1A, Risk Factors
  41. [41] Item 1A, Risk Factors
  42. [42] Item 1A, Risk Factors
  43. [43] Item 8, Note 10 — Debt
  44. [44] Item 1A, Risk Factors
  45. [45] Item 1A, Risk Factors
  46. [46] Item 7, MD&A — Overview
  47. [47] Item 7, MD&A — Overview
  48. [48] Item 7, MD&A — Overview
  49. [49] Item 7, MD&A — Overview
  50. [50] Item 7, MD&A — Overview
  51. [51] Item 8, Consolidated Statements of Comprehensive Income
  52. [52] Item 8, Consolidated Statements of Comprehensive Income
  53. [53] Item 8, Consolidated Statements of Comprehensive Income
  54. [54] Item 8, Consolidated Statements of Comprehensive Income
  55. [55] Item 8, Consolidated Statements of Comprehensive Income
  56. [56] Item 8, Consolidated Statements of Comprehensive Income
  57. [57] Item 8, Consolidated Statements of Comprehensive Income
  58. [58] Item 8, Consolidated Statements of Comprehensive Income
  59. [59] Item 7, MD&A — Results of Operations
  60. [60] Item 7, MD&A — Results of Operations
  61. [61] Item 8, Consolidated Statements of Cash Flows
  62. [62] Item 8, Consolidated Balance Sheets
  63. [63] Item 8, Note 10 — Debt
  64. [64] Item 7, MD&A — Liquidity and Capital Resources
  65. [65] Item 8, Consolidated Statements of Comprehensive Income
  66. [66] Item 7, MD&A — Results of Operations
  67. [67] Item 8, Consolidated Statements of Comprehensive Income
  68. [68] Item 7, MD&A — Results of Operations
  69. [69] Item 8, Consolidated Statements of Comprehensive Income
  70. [70] Item 8, Consolidated Statements of Comprehensive Income
  71. [71] Item 8, Consolidated Statements of Cash Flows
  72. [72] Item 8, Note 20 — Segment Data
  73. [73] Item 8, Note 20 — Segment Data

Analysis on 6/8/2026